1 10 48 https://ciencia.lugoneseditorial.com.ar/files/original/eef525ada63d083672c355c87d5f9a98.pdf 7877cc63b77ec708418ed0f4b191410e Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/dermatologia/acido-hialuronico-eficacia-seguridad/">https://lugoneseditorial.com.ar/novedades/dermatologia/acido-hialuronico-eficacia-seguridad/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Eficacia, seguridad y satisfacción con el uso de Hyaluromax Skin Builder L® Subject The topic of the resource Estudio que confirma la eficacia, seguridad y satisfacción con el uso de complejos híbridos de ácido hialurónico de 1800 kDa con AH de 2500 kDa Description An account of the resource Estudio que confirma la eficacia, seguridad y satisfacción con el uso de complejos híbridos de ácido hialurónico de 1800 kDa con AH de 2500 kDa Creator An entity primarily responsible for making the resource Dra. Ana Karina Sanz, Médica Cirujana, MS Centro Médico de Estética Avanzada, Región Metropolitana, Buin, Chile Source A related resource from which the described resource is derived I. Kim BJ, Choi JH, Lee Y. Development of facial rejuvenation procedures. Thirty years of clinical experience with face lifts. Arch Plast Surg 2015 Sep;42(5):521-31. doi: 10.5999/ aps.2015.42.5.521. II. Alves R, Castro-Esteves T, Trelles MA. Intrinsec and extrinsec factors related to cutaneous aging. Cir Plast Iberol 2013;39(1):89-102. III. Ruiz-Martínez MA, Morales-Hernández MA. Approach to the treatment of skin aging. Ars Pharm 2025;56(4). IV. Kerscher M, Bayrhammer J, Reuther T. Rejuvenating influence of a stabilized hyaluronic acid-based gel of nonanimal origin on facial skin aging. Dermatol Surg 2008 May;34(5):720-6. doi: 10.1111/j.1524-4725.2008.34176.x. V. Wang F, Garza LA, Kang S, Varani J, Orringer JS, Fisher GJ, Voorhees JJ. In vivo stimulation of de novo collagen production caused by cross-linked hyaluronic acid dermal filler injections in photodamaged human skin. Arch Dermatol 2007 Feb;143(2):155-63. doi: 10.1001/ archderm.143.2.155. VI. Goltsova E, Shemonaeva O. Hybrid cooperative complexes of H-HA and L-HA (Profhilo®) and the BAP technique for facial skin bioremodeling: a clinical experience at the NEO-Clinic (Tyumen, Russia). Esperienze Dermatologiche 2019;21:47-53. VII. Trévidic P, Kaufman-Janette J, Weinkle S, Wu R, Dhillon B, Antunes S, Macé E, Maffert P. Injection guidelines for treating midface volume deficiency with hyaluronic acid fillers. The ATP Approach (Anatomy, Techniques, Products). Aesthet Surg J 2022 Aug 1;42(8):920-934. doi: 10.1093/asj/sjac007. VIII. Maytin EV. Hyaluronan: more than just a wrinkle filler. Glycobiology 2016;26(6):553-559. doi: 10.1093/glycob/ cww033. IX. www.futerman.com.ar/hyaluromax. X. Administración Nacional de Medicamentos, Alimentos y Tecnología Médica. Instrucciones de uso de Hyaluromax Skin Builder L autorizadas por ANMAT. Disponible en:https://helena.anmat.gob.ar/Boletin/. XI. Cassuto D, Bellia G, Schiraldi C. An overview of soft tissue fillers for cosmetic dermatology: from filling to regenerative medicine. Clin Cosmet Investig Dermatol 2021 22;14:1857-1866. doi: 10.2147/CCID.S276676. XII. Enhance Me. Training Academy. Técnica BAP 8. Disponible en: https://www.enhance-me-training.com/ lessons/the-bap-technique/#:~:text=The%20BAP%20 technique%20(bio%20aesthetic%20points)&text=It%20 is%20injected%20in%20the,and%20improvement%20 of%20skin%20turgor. XIII. Vera RV, Morales SMA, Santa CFJ, et al. Escalas clínicas para evaluar el envejecimiento cutáneo: una revisión de la literatura. Rev Cent Dermatol Pascua 2021;30(2):68- 75. doi:10.35366/101176 Publisher An entity responsible for making the resource available Lic. María Fernanda Cristoforetti, Editora de Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource 11/12/2024 Contributor An entity responsible for making contributions to the resource Futerman Language A language of the resource Español Identifier An unambiguous reference to the resource within a given context <a href="https://doi.org/10.47196/0587">https://doi.org/10.47196/0587</a> 1800 kDa ácido hialurónico AH de 2500 kDa Ana Karina Sanz eficacia envejecimiento de la piel Futerman 2 Lidocaína Marcelo Robles seguridad Técnica BAP https://ciencia.lugoneseditorial.com.ar/files/original/7a8c9819cb60821653ed501a1246055f.pdf ca0da9cf851be99a18c55db25c60deb6 Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/dermatologia/acido-hialuronico-facial/">https://lugoneseditorial.com.ar/novedades/dermatologia/acido-hialuronico-facial/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Estudio de la seguridad y eficacia del ácido hialurónico reticulado 30 mg/ml para relleno facial Description An account of the resource Introducción: el envejecimiento es un proceso multifactorial que afecta tanto la funcionalidad como la estética del cuerpo, incluida la piel, influido por factores intrínsecos (genética) y extrínsecos (ambiente). Los materiales de relleno, especialmente los producidos a base de ácido hialurónico (AH), son los más elegidos en procedimientos estéticos por su eficacia, seguridad y facilidad de uso. En el tercio medio facial, los signos más visibles del envejecimiento, como las arrugas y los surcos, suelen tratarse con AH reticulado (AHR), reconocido mundialmente por su capacidad de corregir pliegues y restaurar el volumen. Su reabsorción depende del tiempo y de los factores individuales y ambientales, ofreciendo resultados duraderos y reduciendo complicaciones en comparación con otros métodos. Objetivos: comprobar la eficacia y seguridad de Cientific Hyaluronic Facial Implant 30® como relleno en varias áreas del rostro y su permanencia en el tiempo. Materiales y métodos: estudio observacional, longitudinal, multicéntrico y prospectivo que incluyó 55 pacientes, de entre 23 y 78 años, con un promedio de 45 años, el 84% era mujer (46) y el 16% hombre (9). Los pacientes pertenecían del tipo I al IV de la clasificación de Fitzpatrick. El estudio se realizó entre enero de 2022 y abril de 2023. Las zonas tratadas fueron: surcos nasolabiales, aumento y perfilado de labios, arrugas superiores del labio y pómulos. Se utilizó ácido hialurónico reticulado (AHR) 30 mg/ml (Cientific Hyaluronic Facial Implant 30®, CH30) para relleno facial. Resultados: la duración del AHR bifásico utilizado en promedio fue de hasta 8 meses con la posibilidad de extenderse a un año con las reaplicaciones correspondientes. La duración de estos efectos también dependió de la edad y el estado de la piel de los pacientes, como así también de algunos hábitos como la exposición al sol o el consumo de tabaco. Conclusiones: Cientific Hyaluronic Facial Implant 30® es un producto seguro. Los efectos adversos remitieron dentro de los 7 días en el 97% de los casos y en el resto dentro de los 14 días. En cuanto a su eficacia como relleno, se comprobó que su duración promedio es de hasta 8 meses en el sitio del implante, la cual depende de la edad del paciente y del estado de su piel. Creator An entity primarily responsible for making the resource - Claudio Dachevsky, Médico Cirujano Plástico, Director General, Clínica Lipo Cirugía Plástica, San Pablo, Brasil Source A related resource from which the described resource is derived 1. Alves R, Castro Esteves T, Trelles MA. Factores intrínsecos y extrínsecos implicados en el envejecimiento cutáneo. Cirugía Plástica Ibero-Latinoamericana 2013;39(1):89 102. doi: 10.4321/S0376-78922013000100013. 2. Rabe JH, Mamelak AJ, McElgunn PJ, Morison WL, Sauder DN. Photoaging: mechanisms and repair. J Am Acad Dermatol 2006 Jul;55(1):1-19. doi: 10.1016/j. jaad.2005.05.010. 3. Sánchez-Carpintero I, Candelas D, Ruiz-Rodríguez R. Dermal fillers: types, indications, and complications. Actas Dermosiflio 2010;101(5):381-393. doi: 10.1016/j. ad.2010.01.004. 4. Kablik J, Monheit GD, Yu L, Chang G, Gershkovich J. Comparative physical properties of hyaluronic acid dermal fillers. Dermatol Surg 2009 Feb;35 Suppl 1:302- 12. doi: 10.1111/j.1524-4725.2008.01046.x. 5. Erazo PJ, de Carvalho AC, et al. Relleno facial con ácido hialurónico: técnica de pilares y malla de sustentación. Principios básicos para obtener una remodelación facial. Cir Plást. Iberolatinoam 2009;35(3):181-194. 6. Clark CP. Animal-based hyaluronic acid fillers: scientific and technical considerations. Plast Reconstr Surg 2007 Nov;120(6 Suppl):27S-32S. doi: 10.1097/01. prs.0000248806.70402.7b. 7. Goa KL, Benfield P. Hyaluronic acid. A review of its pharmacology and use as a surgical aid in ophthalmology, and its therapeutic potential in joint disease and wound healing. Drugs 1994 Mar;47(3):536- 66. doi: 10.2165/00003495-199447030-00009. 8. Guerra-Tapia A, Gómez de la Fuente E. The role of hyaluronic acid in dermatology. Actas Dermosiflio 1998;89(9):435-443. 9. Reed RK, Lilja K, Laurent TC. Hyaluronan in the rat with special reference to the skin. Acta Physiol Scand. 1988 Nov;134(3):405-11. doi: 10.1111/j.1748-1716.1988. tb08508.x. 10. Tammi R, Ripellino JA, Margolis RU, Tammi M. Localization of epidermal hyaluronic acid using the hyaluronate binding region of cartilage proteoglycan as a specific probe. J Invest Dermatol 1988 Mar;90(3):412-4. doi: 10.1111/1523-1747.ep12456530. 11. Ruvira-Martínez E. Certificación de experto en Medicina Estética Facial 2018. Disponible en: www.eimec.com/ wp-content/uploads/2020/05/CEMEF18_Trabajo_final_ Dr_Ernesto_Ruvira.pdf. 12. Lamberg SI, Yuspa SH, Hascall VC. Synthesis of hyaluronic acid is decreased and synthesis of proteoglycans is increased when cultured mouse epidermal cells differentiate. J Invest Dermatol 1986 Jun;86(6):659-67. doi: 10.1111/1523-1747.ep12275707. 13. Aguilar-Donis A, García-Gutiérrez P, et al. Revisión de materiales de relleno. DCMQ 2015;13(1). 14. Mayo Clinic. Hyaluronic acid (injection route). Disponible en: https://www.mayoclinic.org/drugssupplements/hyaluronic-acid-injection-route/ description/drg-20074557. 15. Dibernardo G, DiBernardo B. Prediction of treatment outcomes for neck rejuvenation utilizing a unique classification system of treatment approach using a 1440-nm side-firing laser. Aesthetic Surgery Journal 2018;38:S43-S51. doi: 10.1093/asj/sjy066. 16. Sundaram H, Shamban A, Schlessinger J, et al. Efficacy and safety of a new resilient hyaluronic acid filler in the correction of moderate-to-severe dynamic perioral rhytides. A 52-week prospective, multicenter, controlled, randomized, evaluator-blinded Study. Dermatol Surg 2022;48(1):87-93. doi: 10.1097/DSS.0000000000003238. 17. Abduljabbar MH, Basendwh MA. Complications of hyaluronic acid fillers and their managements, Journal of Dermatology & Dermatologic Surgery 2016;20(2). doi: 10.1016/j.jdds.2016.01.001 18. Peña F. Factores relacionados a la durabilidad del ácido hialurónico reticulado. Rev Facultad de Medicina de la Universidad de lberoamérica 2023;2;13-21. doi 10.54376/ rcmui.v2i2.148. 19. Scardovi S, Goglian A, Gendra P, Gendra C. Estudio clínico de eficacia, duración y efectos adversos del implante de ácido hialurónico en área buco-maxilofacial. Odontoestomatología 2019;19(30):77-90. 20. Bertossi D, Sbarbati A, Cerini R, et al. Hyaluronic acid: in vitro and in vivo analysis, biochemical properties and histological and morphological evaluation of injected filler. Eur J Dermatol 2013 Jul-Aug;23(4):449-55. doi: 10.1684/ejd.2013.2059. 21. Ballin AC, Cazzaniga A, Brandt FS. Long-term efficacy, safety and durability of Juvéderm® XC. Clin Cosmet Investig Dermatol 2013 Aug 5;6:183-9. doi: 10.2147/ CCID.S33568. 22. Herrmann JL, Hoffmann RK, Ward CE, Schulman JM, Grekin RC. Biochemistry, physiology, and tissue interactions of contemporary biodegradable injectable dermal fillers. Dermatol Surg 2018 Nov;44 Suppl 1:S19-S31. doi: 10.1097/DSS.0000000000001582. 23. Park KY, Seok J, Kim BJ, Youn CS. Differences in hyaluronic acid filler persistence depending upon facial site. A consideration of anatomical factors. Dermatol Surg 2017; 43(10):1306-1308. doi: 10.1097/ DSS.0000000000001151. Date A point or period of time associated with an event in the lifecycle of the resource 23/04/2025 Identifier An unambiguous reference to the resource within a given context <a href="https://doi.org/10.47196/0591">https://doi.org/10.47196/0591</a> ácido hialurónico arrugas estética labios pómulos rellenos surcos https://ciencia.lugoneseditorial.com.ar/files/original/8948d29d3f8e50f8b0edb27e5d8e893e.pdf c6df3afbf474e320d172268355cfb9bc Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Subject The topic of the resource Dermatología Title A name given to the resource Trabajos originales Publisher An entity responsible for making the resource available Sello Editorial Lugones Date A point or period of time associated with an event in the lifecycle of the resource 12/12/2023 Contributor An entity responsible for making contributions to the resource Futerman International Products Format The file format, physical medium, or dimensions of the resource Página web: https://www.lugoneseditorial.com.ar/novedades/estudio-prospectivo-evaluacion-de-la-eficacia-y-longevidad-del-acido-hialuronico-reticulado-en-relleno-de-surcos-nasolabiales/ Language A language of the resource Español Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Estudio prospectivo: evaluación de la eficacia y longevidad del ácido hialurónico reticulado en relleno de surcos nasolabiales Subject The topic of the resource Dermatología Description An account of the resource Introducción: la elección de métodos mínimamente invasivos posiciona a los rellenos de ácido hialurónico (AH) como técnica líder de rejuvenecimiento facial. Los rellenos inyectables de AH se han utilizado ampliamente en el tratamiento clínico de las arrugas faciales. Sin embargo, la información adicional y la evidencia clínica sobre la longevidad del relleno de AH después de la inyección son limitadas. Objetivos: demostrar la eficacia, seguridad y longevidad de AH reticulado (AHR) 30 mg/ml (Estrianon Hyaluronic Implant 30® Allanmar International Company S.R.L., Argentina) para el relleno de surcos nasolabiales (SNL). Diseño: ensayo clínico multicéntrico, prospectivo y controlado de 12 meses de duración. Materiales y métodos: se incluyeron 160 pacientes (132 mujeres y 28 hombres, repartidos en cohortes de 30, 30 y 100 cada una) y se les aplicó un gel inyectable de AHR 30 mg/ml en la corrección de los SNL para evaluar la seguridad, eficacia y longevidad del producto. Resultados: se observó una corrección relevante de la depresión en los surcos que se mantuvo hasta el final del estudio. El nivel medio de mejora fue clínicamente significativo en el 94% de los casos. La gravedad de los SNL se redujo en aproximadamente 2 puntos hasta el rango de leve o apenas visible. Conclusiones: Estrianon Hyaluronic Implant 30® demostró ser un relleno seguro, eficaz y de longevidad considerable. A los 12 meses aún se observó corrección significativa y el tratamiento fue bien tolerado por los pacientes. Creator An entity primarily responsible for making the resource Claudio Dachevsky, Héctor Llovera Source A related resource from which the described resource is derived I. Sharma P, Sharma S. Comparative study of a new dermal filler Uma Jeunesse® and Juvéderm®. J Cosmet Dermatol 2011 Jun;10(2):118-25. doi: 10.1111/j.14732165.2011.00556.x. II. Chung C, Lee JH. A single-center, randomized, doubleblind clinical trial to compare the efficacy and safety of a new monophasic hyaluronic acid filler and biphasic filler in correcting nasolabial fold. Aesth Plast Surg 2021;45:2902-2908. doi: 10.1007/s00266-021-02252-0 III. Goldberg DJ. Breakthroughs in US dermal fillers for facial soft-tissue augmentation. J Cosmet Laser Ther 2009 Dec;11(4):240-7. doi: 10.3109/14764170903341731. IV. Gold M. The science and art of hyaluronic acid dermal filler use in esthetic applications. J Cosmet Dermatol 2009 Dec;8(4):301-7. doi: 10.1111/j.14732165.2009.00464.x. V. Beer K. Dermal fillers and combinations of fillers for facial rejuvenation. Dermatol Clin 2009 Oct;27(4):42732. doi: 10.1016/j.det.2009.08.011. VI. Grunebaum LD, Bogdan Allemann I, Dayan S, Mandy S, Baumann L. The risk of alar necrosis associated with dermal filler injection. Dermatol Surg 2009 Oct;35(Suppl 2):1635-40. doi: 10.1111/j.1524-4725.2009.01342.x. VII. Hirsch R, Stier M. Complications and their management in cosmetic dermatology. Dermatol Clin 2009 Oct;27(4):507-20. doi: 10.1016/j.det.2009.08.013. VIII. Qiao J, Jia QN, Jin HZ, Li F, He CX, Yang J, Zuo YG, Fu LQ. Long-term follow-up of longevity and diffusion pattern of hyaluronic acid in nasolabial fold correction through high-frequency ultrasound. Plast Reconstr Surg 2019 Aug;144(2):189e-196e. doi: 10.1097/ PRS.0000000000005848. IX. Young SR, Bolton PA, Downie J. Use of high-frequency ultrasound in the assessment of injectable dermal fillers. Skin Res Technol 2008 Aug;14(3):320-3. doi: 10.1111/j.1600-0846.2008.00297.x. X. Marinho A, Nunes C, Reis S. Hyaluronic acid: a key ingredient in the therapy of inflammation. Biomolecules 2021 Oct 15;11(10):1518. doi: 10.3390/biom11101518. XI. Day DJ, Littler CM, Swift RW, Gottlieb S. The Wrinkle Severity Rating Scale: a validation study. Am J Clin Dermatol 2004;5(1):49-52. doi: 10.2165/00128071200405010-00007. XII. Savoia A, Accardo C, Vannini F, Di Pasquale B, Baldi A. Outcomes in thread lift for facial rejuvenation: a study performed with happy lift™ tevitalizing. Dermatology Ther (Heidelb) 2014;4(1):103-14. doi: 10.1007/s13555014-0041-6. XIII. Sharma AN, Patel BC. Laser Fitzpatrick skin type recommendations (updated 2023 Mar 6). In: StatPearls (Internet). Treasure Island (FL): StatPearls Publishing; 2023 Jan. Disponible en: https://www.ncbi.nlm.nih.gov/ books/NBK557626/. XIV. Mark G. Rubin, treatment of nasolabial folds with fillers. Aesthetic Surgery Journal 2004;24(5):489-493. doi: 10.1016/j.asj.2004.06.004. XV. Shaw RB Jr, Katzel EB, Koltz PF, Yaremchuk MJ, Girotto JA, Kahn DM, Langstein HN. Aging of the facial skeleton: aesthetic implications and rejuvenation strategies. Plast Reconstr Surg 2011 Jan;127(1):374-383. doi: 10.1097/PRS.0b013e3181f95b2d. XVI. Brandt FS, Cazzaniga A. Hyaluronic acid fillers: Restylane and Perlane. Facial Plast Surg Clin North Am 2007 Feb;15(1):63-76. doi: 10.1016/j.fsc.2006.11.002. XVII. Allergan. Instrucciones de uso. Disponible en https:// www.rxabbvie.com/pdf/juvederm-ultra_dfu.pdf. XVIII. Allergan. Instrucciones de uso. Disponible en: https:// www.rxabbvie.com/pdf/juvederm-ultra-plus-xc_dfu.pdf. XIX. Galderma. Instrucciones de uso. Disponible en: https:// www.galderma.com/us/sites/default/files/2018-11/ Restylane_IFU.pdf. XX. Narins RS, Brandt F, Leyden J, Lorenc ZP, Rubin M, Smith S. A randomized, double-blind, multicenter comparison of the efficacy and tolerability of Restylane versus Zyplast for the correction of nasolabial folds. Dermatol Surg 2003 Jun;29(6):588-95. doi: 10.1046/j.15244725.2003.29150.x. XXI. Li D, Xie Y, Li Q, Sun J, Jiang P, Jia Y, Murphy DK, Li Q. Safety and effectiveness of Juvéderm Ultra Plus injectable gel in correcting severe nasolabial folds in Chinese subjects. Plast Reconstr Surg Glob Open 2017 Jan 16;5(1):e1133. doi: 10.1097/GOX.0000000000001133. XXII. Goodman GJ, Bekhor P, Rich M, Rosen RH, Halstead MB, Rogers JD. A comparison of the efficacy, safety, and longevity of two different hyaluronic acid dermal fillers in the treatment of severe nasolabial folds: a multicenter, prospective, randomized, controlled, single-blind, within-subject study. Clin Cosmet Investig Dermatol 2011;4:197-205. doi: 10.2147/CCID.S26055. XXIII. Baumann LS, Shamban AT, Lupo MP, Monheit GD, Thomas JA, Murphy DK, Walker PS; Juvéderm vs. Zyplast nasolabial fold study group. Comparison of smooth-gel hyaluronic acid dermal fillers with cross-linked bovine collagen: a multicenter, double-masked, randomized, within-subject study. Dermatol Surg 2007 Dec;33(Suppl 2):S128-35. doi: 10.1111/j.1524-4725.2007.33352.x. XXIV. Lupo MP, Smith SR, Thomas JA, Murphy DK, Beddingfield FC III. Effectiveness of Juvéderm Ultra Plus dermal filler in the treatment of severe nasolabial folds. Plast Reconstr Surg 2008 Jan;121(1):289-297. doi: 10.1097/01. prs.0000294968.76862.83. XXV. Pinsky MA, Thomas JA, Murphy DK, Walker PS; Juvéderm vs. Zyplast Nasolabial Fold Study Group. Juvéderm injectable gel: a multicenter, double-blind, randomized study of safety and effectiveness. Aesthet Surg J 2008 Jan-Feb;28(1):17-23. doi: 10.1016/j.asj.2007.09.005. XXVI. Solish N, Bertucci V, Percec I, Wagner T, Nogueira A, Mashburn J. Dynamics of hyaluronic acid fillers formulated to maintain natural facial expression. J Cosmet Dermatol 2019 Jun;18(3):738-746. doi: 10.1111/ jocd.12961. Publisher An entity responsible for making the resource available Editorial Lugones Date A point or period of time associated with an event in the lifecycle of the resource 12/12/2023 Contributor An entity responsible for making contributions to the resource Allanmar International Company S.R.L Rights Information about rights held in and over the resource Registros legales: Sello Editorial Lugones®. Director: Facundo Lugones. Editora: Lic. María Fernanda Cristoforetti. Propietaria: Editorial Biotecnológica S.R.L. Domicilio legal: Av. Curapaligüe 202, 9° B (1406), Ciudad de Buenos Aires, Argentina. Autores del artículo de Lugones Editorial: Marcelo Robles, Claudio Dachevsky, Héctor Llovera. Derechos de reproducción: Sello Editorial Lugones®, Editorial Biotecnológica S.R.L. Se prohíbe la reproducción total o parcial de los artículos sin las autorizaciones de la autora y de la editorial. Obra registrada en la Dirección Nacional del Derecho de Autor, Ministerio de Justicia y Derechos Humanos de la República Argentina. Registro de Obra Publicada-Página Web en el Legajo Nº: RL-2021-41251755-APN-DNDA#MJ. Registro de Publicaciones Periódicas en el Legajo Nº: RL-2023-71140630-APN-DNDA#MJ, Ciudad de Buenos Aires, Argentina. Format The file format, physical medium, or dimensions of the resource Página web Language A language of the resource Español e Inglés Type The nature or genre of the resource Científico Identifier An unambiguous reference to the resource within a given context <a href="https://www.lugoneseditorial.com.ar/novedades/estudio-prospectivo-evaluacion-de-la-eficacia-y-longevidad-del-acido-hialuronico-reticulado-en-relleno-de-surcos-nasolabiales/#">https://www.lugoneseditorial.com.ar/novedades/estudio-prospectivo-evaluacion-de-la-eficacia-y-longevidad-del-acido-hialuronico-reticulado-en-relleno-de-surcos-nasolabiales/#</a> Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Argentina, 2023 ácido hialurónico Global Aesthetic Improvement Scale surcos nasolabiales https://ciencia.lugoneseditorial.com.ar/files/original/30be7fd9a44d120a9881dd0404a36ae2.pdf c6df3afbf474e320d172268355cfb9bc Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Subject The topic of the resource Dermatología Title A name given to the resource Trabajos originales Publisher An entity responsible for making the resource available Sello Editorial Lugones Date A point or period of time associated with an event in the lifecycle of the resource 12/12/2023 Contributor An entity responsible for making contributions to the resource Futerman International Products Format The file format, physical medium, or dimensions of the resource Página web: https://www.lugoneseditorial.com.ar/novedades/estudio-prospectivo-evaluacion-de-la-eficacia-y-longevidad-del-acido-hialuronico-reticulado-en-relleno-de-surcos-nasolabiales/ Language A language of the resource Español Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Prospective study: evaluation of the efficacy and longevity of cross-linked hyaluronic acid in filling nasolabial folds Subject The topic of the resource Dermatology Description An account of the resource Introduction: The choice of minimally invasive methods positions hyaluronic acid (HA) fillers as a leading facial rejuvenation technique. Injectable HA fillers have been widely used in the clinical treatment of facial wrinkles. However, additional information and clinical evidence on the longevity of HA filler after injection is limited. Objectives: demonstrate the efficacy, safety and longevity of cross-linked HA (AHR) 30 mg/ml (Estrianon Hyaluronic Implant 30® Allanmar International Company S.R.L., Argentina) for filling nasolabial folds (SNL). Design: multicenter, prospective, controlled clinical trial of 12 months duration. Materials and methods: 160 patients were included (132 women and 28 men, divided into cohorts of 30, 30 and 100 each) and an injectable gel of AHR 30 mg/ml was applied in the correction of SNL to evaluate safety. , effectiveness and longevity of the product. Results: a relevant correction of the depression in the sulci was observed that was maintained until the end of the study. The mean level of improvement was clinically significant in 94% of cases. The severity of NLS was reduced by approximately 2 points to the range of mild or barely noticeable. Conclusions: Estrianon Hyaluronic Implant 30® proved to be a safe, effective filler with considerable longevity. At 12 months, significant correction was still observed and the treatment was well tolerated by patients. Creator An entity primarily responsible for making the resource Claudio Dachevsky, Héctor Llovera Source A related resource from which the described resource is derived I. Sharma P, Sharma S. Comparative study of a new dermal filler Uma Jeunesse® and Juvéderm®. J Cosmet Dermatol 2011 Jun;10(2):118-25. doi: 10.1111/j.14732165.2011.00556.x. II. Chung C, Lee JH. A single-center, randomized, doubleblind clinical trial to compare the efficacy and safety of a new monophasic hyaluronic acid filler and biphasic filler in correcting nasolabial fold. Aesth Plast Surg 2021;45:2902-2908. doi: 10.1007/s00266-021-02252-0 III. Goldberg DJ. Breakthroughs in US dermal fillers for facial soft-tissue augmentation. J Cosmet Laser Ther 2009 Dec;11(4):240-7. doi: 10.3109/14764170903341731. IV. Gold M. The science and art of hyaluronic acid dermal filler use in esthetic applications. J Cosmet Dermatol 2009 Dec;8(4):301-7. doi: 10.1111/j.14732165.2009.00464.x. V. Beer K. Dermal fillers and combinations of fillers for facial rejuvenation. Dermatol Clin 2009 Oct;27(4):42732. doi: 10.1016/j.det.2009.08.011. VI. Grunebaum LD, Bogdan Allemann I, Dayan S, Mandy S, Baumann L. The risk of alar necrosis associated with dermal filler injection. Dermatol Surg 2009 Oct;35(Suppl 2):1635-40. doi: 10.1111/j.1524-4725.2009.01342.x. VII. Hirsch R, Stier M. Complications and their management in cosmetic dermatology. Dermatol Clin 2009 Oct;27(4):507-20. doi: 10.1016/j.det.2009.08.013. VIII. Qiao J, Jia QN, Jin HZ, Li F, He CX, Yang J, Zuo YG, Fu LQ. Long-term follow-up of longevity and diffusion pattern of hyaluronic acid in nasolabial fold correction through high-frequency ultrasound. Plast Reconstr Surg 2019 Aug;144(2):189e-196e. doi: 10.1097/ PRS.0000000000005848. IX. Young SR, Bolton PA, Downie J. Use of high-frequency ultrasound in the assessment of injectable dermal fillers. Skin Res Technol 2008 Aug;14(3):320-3. doi: 10.1111/j.1600-0846.2008.00297.x. X. Marinho A, Nunes C, Reis S. Hyaluronic acid: a key ingredient in the therapy of inflammation. Biomolecules 2021 Oct 15;11(10):1518. doi: 10.3390/biom11101518. XI. Day DJ, Littler CM, Swift RW, Gottlieb S. The Wrinkle Severity Rating Scale: a validation study. Am J Clin Dermatol 2004;5(1):49-52. doi: 10.2165/00128071200405010-00007. XII. Savoia A, Accardo C, Vannini F, Di Pasquale B, Baldi A. Outcomes in thread lift for facial rejuvenation: a study performed with happy lift™ tevitalizing. Dermatology Ther (Heidelb) 2014;4(1):103-14. doi: 10.1007/s13555014-0041-6. XIII. Sharma AN, Patel BC. Laser Fitzpatrick skin type recommendations (updated 2023 Mar 6). In: StatPearls (Internet). Treasure Island (FL): StatPearls Publishing; 2023 Jan. Disponible en: https://www.ncbi.nlm.nih.gov/ books/NBK557626/. XIV. Mark G. Rubin, treatment of nasolabial folds with fillers. Aesthetic Surgery Journal 2004;24(5):489-493. doi: 10.1016/j.asj.2004.06.004. XV. Shaw RB Jr, Katzel EB, Koltz PF, Yaremchuk MJ, Girotto JA, Kahn DM, Langstein HN. Aging of the facial skeleton: aesthetic implications and rejuvenation strategies. Plast Reconstr Surg 2011 Jan;127(1):374-383. doi: 10.1097/PRS.0b013e3181f95b2d. XVI. Brandt FS, Cazzaniga A. Hyaluronic acid fillers: Restylane and Perlane. Facial Plast Surg Clin North Am 2007 Feb;15(1):63-76. doi: 10.1016/j.fsc.2006.11.002. XVII. Allergan. Instrucciones de uso. Disponible en https:// www.rxabbvie.com/pdf/juvederm-ultra_dfu.pdf. XVIII. Allergan. Instrucciones de uso. Disponible en: https:// www.rxabbvie.com/pdf/juvederm-ultra-plus-xc_dfu.pdf. XIX. Galderma. Instrucciones de uso. Disponible en: https:// www.galderma.com/us/sites/default/files/2018-11/ Restylane_IFU.pdf. XX. Narins RS, Brandt F, Leyden J, Lorenc ZP, Rubin M, Smith S. A randomized, double-blind, multicenter comparison of the efficacy and tolerability of Restylane versus Zyplast for the correction of nasolabial folds. Dermatol Surg 2003 Jun;29(6):588-95. doi: 10.1046/j.15244725.2003.29150.x. XXI. Li D, Xie Y, Li Q, Sun J, Jiang P, Jia Y, Murphy DK, Li Q. Safety and effectiveness of Juvéderm Ultra Plus injectable gel in correcting severe nasolabial folds in Chinese subjects. Plast Reconstr Surg Glob Open 2017 Jan 16;5(1):e1133. doi: 10.1097/GOX.0000000000001133. XXII. Goodman GJ, Bekhor P, Rich M, Rosen RH, Halstead MB, Rogers JD. A comparison of the efficacy, safety, and longevity of two different hyaluronic acid dermal fillers in the treatment of severe nasolabial folds: a multicenter, prospective, randomized, controlled, single-blind, within-subject study. Clin Cosmet Investig Dermatol 2011;4:197-205. doi: 10.2147/CCID.S26055. XXIII. Baumann LS, Shamban AT, Lupo MP, Monheit GD, Thomas JA, Murphy DK, Walker PS; Juvéderm vs. Zyplast nasolabial fold study group. Comparison of smooth-gel hyaluronic acid dermal fillers with cross-linked bovine collagen: a multicenter, double-masked, randomized, within-subject study. Dermatol Surg 2007 Dec;33(Suppl 2):S128-35. doi: 10.1111/j.1524-4725.2007.33352.x. XXIV. Lupo MP, Smith SR, Thomas JA, Murphy DK, Beddingfield FC III. Effectiveness of Juvéderm Ultra Plus dermal filler in the treatment of severe nasolabial folds. Plast Reconstr Surg 2008 Jan;121(1):289-297. doi: 10.1097/01. prs.0000294968.76862.83. XXV. Pinsky MA, Thomas JA, Murphy DK, Walker PS; Juvéderm vs. Zyplast Nasolabial Fold Study Group. Juvéderm injectable gel: a multicenter, double-blind, randomized study of safety and effectiveness. Aesthet Surg J 2008 Jan-Feb;28(1):17-23. doi: 10.1016/j.asj.2007.09.005. XXVI. Solish N, Bertucci V, Percec I, Wagner T, Nogueira A, Mashburn J. Dynamics of hyaluronic acid fillers formulated to maintain natural facial expression. J Cosmet Dermatol 2019 Jun;18(3):738-746. doi: 10.1111/ jocd.12961. Publisher An entity responsible for making the resource available Editorial Lugones Date A point or period of time associated with an event in the lifecycle of the resource 12/12/2023 Contributor An entity responsible for making contributions to the resource Allanmar International Company S.R.L Rights Information about rights held in and over the resource Legal records: Lugones® Editorial Seal. Director: Facundo Lugones. Editor: Lic. María Fernanda Cristoforetti. Owner: Editorial Biotecnológica S.R.L. Legal address: Av. Curapaligüe 202, 9° B (1406), City of Buenos Aires, Argentina. Authors of the Lugones article Editorial: Marcelo Robles, Claudio Dachevsky, Héctor Llovera Reproduction rights: Lugones® Editorial Seal, Editorial Biotecnológica S.R.L. Total or partial reproduction of the articles is prohibited without the authorization of the author and the publisher. Work registered in the National Directorate of Copyright, Ministry of Justice and Human Rights of the Argentine Republic. Registration of Published Work-Web Page in File No.: RL-2021-41251755-APN-DNDA#MJ. Registration of Periodical Publications in File No.: RL-2023-71140630-APN-DNDA#MJ, City of Buenos Aires, Argentina. Format The file format, physical medium, or dimensions of the resource Website Language A language of the resource English and spanish Type The nature or genre of the resource Scientific Identifier An unambiguous reference to the resource within a given context <a href="https://www.lugoneseditorial.com.ar/novedades/estudio-prospectivo-evaluacion-de-la-eficacia-y-longevidad-del-acido-hialuronico-reticulado-en-relleno-de-surcos-nasolabiales/#">https://www.lugoneseditorial.com.ar/novedades/estudio-prospectivo-evaluacion-de-la-eficacia-y-longevidad-del-acido-hialuronico-reticulado-en-relleno-de-surcos-nasolabiales/#</a> Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Argentina, 2023 Global Aesthetic Improvement hyaluronic acid nasolabial folds https://ciencia.lugoneseditorial.com.ar/files/original/0c8ebdf3ac1c2f28c6567ec2647bc068.pdf fca41daa9e2aeeea547aff1d1c9010d9 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Subject The topic of the resource Dermatología Title A name given to the resource Trabajos originales Publisher An entity responsible for making the resource available Sello Editorial Lugones Date A point or period of time associated with an event in the lifecycle of the resource 12/12/2023 Contributor An entity responsible for making contributions to the resource Futerman International Products Format The file format, physical medium, or dimensions of the resource Página web: https://www.lugoneseditorial.com.ar/novedades/estudio-prospectivo-evaluacion-de-la-eficacia-y-longevidad-del-acido-hialuronico-reticulado-en-relleno-de-surcos-nasolabiales/ Language A language of the resource Español Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Estudio de seguridad y eficacia del ácido hialurónico reticulado en relleno de surcos nasolabiales Subject The topic of the resource Dermatología Description An account of the resource Introducción: el envejecimiento facial provoca cambios celulares y anatómicos que resultan en la pérdida de volumen de los tejidos blandos. Ante la demanda estética, el ácido hialurónico (AH) es una muy buena opción para el relleno de surcos y arrugas faciales. Objetivos: comprobar la eficacia y seguridad de la aplicación de ácido hialurónico reticulado (AHR) para el relleno de surcos nasolabiales (SNL), y su permanencia en el tiempo. Diseño: clínico observacional y descriptivo, longitudinal y prospectivo, de 12 meses de duración. Materiales y métodos: se estudió un total de 100 pacientes (86 mujeres y 14 hombres) con SNL de moderados a graves, entre julio de 2018 y diciembre de 2019. Se utilizó AHR 30 mg/ml para relleno facial (Estrianon Hyaluronic Implant 30®, Allanmar International Company S.R.L., Argentina). Resultados: los efectos adversos remitieron a los 7 días en el 97% de los pacientes y en el resto a los 14 días. La aplicación inicial fue de hasta 1 ml por surco en los casos más graves. En cuanto a su eficacia como relleno, se comprobó que su duración promedio es de hasta 8 meses con las reaplicaciones correspondientes. Conclusiones: Estrianon Hyaluronic Implant 30® es un producto seguro. Su duración depende, en gran medida, de la edad del paciente, sus hábitos y el estado de su piel, superando los 8 meses y pudiendo alcanzar el año. Creator An entity primarily responsible for making the resource Editora: María Fernanda Cristoforetti Source A related resource from which the described resource is derived I. Scardovi S, Goglian A, Gendra P, Gendra C. Clinical study of the efficacy, duration and adverse effects of hyaluronic acid implants in the oral-maxillofacial área. Odontoestomatol 2017;19(30):78-91. doi: 10.22592/ o2017n30a9. II. Trévidic P, Kaufman-Janette J, Weinkle S, Wu R, Dhillon B, Antunes S, Macé E, Maffert P. Injection guidelines for treating midface volume deficiency with hyaluronic acid fillers: The ATP Approach (Anatomy, Techniques, Products). Aesthet Surg J 2022 Aug 1;42(8):920-934. doi: 10.1093/asj/sjac007. III. Faivre J, Gallet M, Tremblais E, Trévidic P, Bourdon F. Advanced concepts in rheology for the evaluation of hyaluronic acid-based soft tissue fillers. Dermatol Surg. 2021 May 1;47(5):e159-e167. doi: 10.1097/ DSS.0000000000002916. IV. Cifuentes-Mimoso T, Signes-Soler F. Estudio de efectos adversos tras tratamiento con implantes cutáneos de ácido hialurónico. Universitat Autonoma de Barcelona. Disponible en: https://semcc.com/master/ files/Hialuronico%20y%20efectos%20adversos%20-%20 Dras.%20Cifuentes%20y%20Signes.pdf. V. Snibson GR, Greaves JL, Soper ND, Prydal JI, Wilson CG, Bron AJ. Precorneal residence times of sodium hyaluronate solutions studied by quantitative gamma scintigraphy. Eye (Lond) 1990;4 (Pt 4):594-602. doi: 10.1038/eye.1990.83. VI. Sourdille P, Santiago PY, Villain F, Yamamichi M, Tahi H, Parel JM, Ducournau Y. Reticulated hyaluronic acid implant in nonperforating trabecular surgery. J Cataract Refract Surg 1999 Mar;25(3):332-9. doi: 10.1016/s08863350(99)80080-7. VII. He Z, Han S, Zhen Z, Ding X, Liang S. The clinical use of sodium hyaluronate eyedrops as a substitute for tears. Yan Ke Xue Bao 1990 Dec;6(3-4):111-2. VIII. Petrella RJ, DiSilvestro MD, Hildebrand C. Effects of hyaluronate sodium on pain and physical functioning in osteoarthritis of the knee: a randomized, doubleblind, placebo-controlled clinical trial. Arch Intern Med 2002 Feb 11;162(3):292-8. doi: 10.1001/archinte.162.3.292. IX. Raynauld JP, Torrance GW, Band PA, Goldsmith CH, Tugwell P, Walker V, Schultz M, Bellamy N; Canadian Knee OA Study Group. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. Osteoarthritis Cartilage 2002 Jul;10(7):506-17. doi: 10.1053/joca.2002.0798. X. Tamer TM. Hyaluronan and synovial joint: function, distribution and healing. Interdiscip Toxicol 2013 Sep;6(3):111-25. doi: 10.2478/intox-2013-0019. XI. Altman RD, Moskowitz R. Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. Hyalgan Study Group. J Rheumatol 1998 Nov;25(11):220312. Erratum in: J Rheumatol 1999 May;26(5):1216. XII. Bogdan-Allemann I, Baumann L. Hyaluronic acid gel (Juvéderm) preparations in the treatment of facial wrinkles and folds. Clin Interv Aging 2008;3(4):629-34. doi: 10.2147/cia.s3118. XIII. Jordan DR. Delayed inflammatory reaction to hyaluronic acid (Restylane). Ophthalmic Plast Reconstr Surg. 2005 Sep;21(5):401-2. doi: 10.1097/01.iop.0000173194.18050.b8. XIV. Ågerup B, Wik O. The MonographnashaTM. 2008. Disponible en: https://docplayer.net/20739410-Nashathe-monograph-1.html. XV. Cornejo P, Alcolea JM, Trelles MA. Perspectivas en el uso de materiales de relleno inyectables para tejidos blandos, desde nuestra experiencia. 1º parte. Cir Plást Iberolatinoam 2011;37(4):393-402. XVI. Smith SR, Jones D, Thomas JA, Murphy DK, Beddingfield FC. Duration of wrinkle correction following repeat treatment with Juvéderm hyaluronic acid fillers. Arch Dermatol Res 2010 Dec;302(10):757-62. doi: 10.1007/ s00403-010-1086-8. XVII. Monheit G, Beer K, Hardas B, Grimes PE, Weichman BM, Lin V, Murphy DK. Safety and effectiveness of the hyaluronic acid dermal filler VYC-17.5L for nasolabial folds. Results of a randomized, controlled study. Dermatol Surg 2018 May;44(5):670-678. doi: 10.1097/ DSS.0000000000001529. XVIII. Galderma. Instrucciones de uso. Disponible en: https:// www.galderma.com/us/sites/default/files/2018-11/ Restylane_IFU.pdf. XIX. Allergan. Instrucciones de uso. Disponible en https:// www.rxabbvie.com/pdf/juvederm-ultra-plus-xc_dfu.pdf. XX. Day DJ, Littler CM, Swift RW, Gottlieb S. The Wrinkle Severity Rating Scale: a validation study. Am J Clin Dermatol 2004;5(1):49-52. doi: 10.2165/00128071200405010-00007. XXI. Savoia A, Accardo C, Vannini F, Di Pasquale B, Baldi A. Outcomes in thread lift for facial rejuvenation: a study performed with happy lift™ tevitalizing. Dermatology Ther (Heidelb) 2014;4(1):103-14. XXII. Sharma AN, Patel BC. Laser Fitzpatrick skin type recommendations (updated 2023 Mar 6). In: StatPearls (Internet). Treasure Island (FL): StatPearls Publishing; 2023 Jan. Disponible en: https://www.ncbi.nlm.nih.gov/ books/NBK557626/. XXIII. Pinsky MA, Thomas JA, Murphy DK, Walker PS; Juvéderm versus Zyplast Nasolabial Fold Study Group. Juvéderm injectable gel: a multicenter, double-blind, randomized study of safety and effectiveness. Aesthet Surg J. 2008 Jan-Feb;28(1):17-23. doi: 10.1016/j.asj.2007.09.005. Publisher An entity responsible for making the resource available Editorial Lugones Date A point or period of time associated with an event in the lifecycle of the resource 12/12/2023 Contributor An entity responsible for making contributions to the resource Allanmar International Company S.R.L Rights Information about rights held in and over the resource Registros legales: Sello Editorial Lugones®. Director: Facundo Lugones. Editora: Lic. María Fernanda Cristoforetti. Propietaria: Editorial Biotecnológica S.R.L. Domicilio legal: Av. Curapaligüe 202, 9° B (1406), Ciudad de Buenos Aires, Argentina. Autores del artículo de Lugones Editorial: Marcelo Robles. Derechos de reproducción: Sello Editorial Lugones®, Editorial Biotecnológica S.R.L. Se prohíbe la reproducción total o parcial de los artículos sin las autorizaciones de la autora y de la editorial. Obra registrada en la Dirección Nacional del Derecho de Autor, Ministerio de Justicia y Derechos Humanos de la República Argentina. Registro de Obra Publicada-Página Web en el Legajo Nº: RL-2021-41251755-APN-DNDA#MJ. Registro de Publicaciones Periódicas en el Legajo Nº: RL-2023-71140630-APN-DNDA#MJ, Ciudad de Buenos Aires, Argentina. Format The file format, physical medium, or dimensions of the resource Página web Language A language of the resource Español e inglés Type The nature or genre of the resource Científico Identifier An unambiguous reference to the resource within a given context <a href="https://www.lugoneseditorial.com.ar/novedades/estudio-de-seguridad-y-eficacia-del-acido-hialuronico-reticulado-en-relleno-de-surcos-nasolabiales/">https://www.lugoneseditorial.com.ar/novedades/estudio-de-seguridad-y-eficacia-del-acido-hialuronico-reticulado-en-relleno-de-surcos-nasolabiales/</a> Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Argentina, 2023 ácido hialurónico reticulado envejecimiento de la piel surcos nasolabiales https://ciencia.lugoneseditorial.com.ar/files/original/d917f48efc9817f0e90e9bca5ef43ffe.pdf fca41daa9e2aeeea547aff1d1c9010d9 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Subject The topic of the resource Dermatología Title A name given to the resource Trabajos originales Publisher An entity responsible for making the resource available Sello Editorial Lugones Date A point or period of time associated with an event in the lifecycle of the resource 12/12/2023 Contributor An entity responsible for making contributions to the resource Futerman International Products Format The file format, physical medium, or dimensions of the resource Página web: https://www.lugoneseditorial.com.ar/novedades/estudio-prospectivo-evaluacion-de-la-eficacia-y-longevidad-del-acido-hialuronico-reticulado-en-relleno-de-surcos-nasolabiales/ Language A language of the resource Español Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Safety and efficacy study of cross-linked hyaluronic acid filler in nasolabial folds Subject The topic of the resource Dermatology Description An account of the resource Introduction: facial aging causes cellular and anatomical changes, resulting in loss of soft tissue volume. Due to aesthetic demand, hyaluronic acid is a very good option for filling facial folds and wrinkles. Objectives: verify the effectiveness and safety of the application of cross-linked hyaluronic acid (CLHA) for filling nasolabial folds and its permanence over time. Design: observational and descriptive clinical, longitudinal and prospective, 12 months long. Materials and methods: a total of 100 patients (86 women and 14 men) with moderate to severe nasolabial folds were studied between July 2018 and December 2019. CLHA 30 mg/ml was used for facial filler (Estrianon Hyaluronic Implant 30®, Allanmar International Company S.R.L., Argentina) Results: the adverse effects subsided within 7 days in 97% of the patients and in the rest of the patients within 14 days. The initial application was up to 1 ml per groove in the most severe cases. Regarding its effectiveness as a filler, its average duration was found to be up to 8 months with the corresponding reapplications. Conclusions: Estrianon Hyaluronic Implant 30® is a safe product, its duration depends largely on the age of the patient, their habits and the condition of their skin, exceeding 8 months and up to a year. Creator An entity primarily responsible for making the resource Editora: María Fernanda Cristoforetti Source A related resource from which the described resource is derived I. Scardovi S, Goglian A, Gendra P, Gendra C. Clinical study of the efficacy, duration and adverse effects of hyaluronic acid implants in the oral-maxillofacial área. Odontoestomatol 2017;19(30):78-91. doi: 10.22592/ o2017n30a9. II. Trévidic P, Kaufman-Janette J, Weinkle S, Wu R, Dhillon B, Antunes S, Macé E, Maffert P. Injection guidelines for treating midface volume deficiency with hyaluronic acid fillers: The ATP Approach (Anatomy, Techniques, Products). Aesthet Surg J 2022 Aug 1;42(8):920-934. doi: 10.1093/asj/sjac007. III. Faivre J, Gallet M, Tremblais E, Trévidic P, Bourdon F. Advanced concepts in rheology for the evaluation of hyaluronic acid-based soft tissue fillers. Dermatol Surg. 2021 May 1;47(5):e159-e167. doi: 10.1097/ DSS.0000000000002916. IV. Cifuentes-Mimoso T, Signes-Soler F. Estudio de efectos adversos tras tratamiento con implantes cutáneos de ácido hialurónico. Universitat Autonoma de Barcelona. Disponible en: https://semcc.com/master/ files/Hialuronico%20y%20efectos%20adversos%20-%20 Dras.%20Cifuentes%20y%20Signes.pdf. V. Snibson GR, Greaves JL, Soper ND, Prydal JI, Wilson CG, Bron AJ. Precorneal residence times of sodium hyaluronate solutions studied by quantitative gamma scintigraphy. Eye (Lond) 1990;4 (Pt 4):594-602. doi: 10.1038/eye.1990.83. VI. Sourdille P, Santiago PY, Villain F, Yamamichi M, Tahi H, Parel JM, Ducournau Y. Reticulated hyaluronic acid implant in nonperforating trabecular surgery. J Cataract Refract Surg 1999 Mar;25(3):332-9. doi: 10.1016/s08863350(99)80080-7. VII. He Z, Han S, Zhen Z, Ding X, Liang S. The clinical use of sodium hyaluronate eyedrops as a substitute for tears. Yan Ke Xue Bao 1990 Dec;6(3-4):111-2. VIII. Petrella RJ, DiSilvestro MD, Hildebrand C. Effects of hyaluronate sodium on pain and physical functioning in osteoarthritis of the knee: a randomized, doubleblind, placebo-controlled clinical trial. Arch Intern Med 2002 Feb 11;162(3):292-8. doi: 10.1001/archinte.162.3.292. IX. Raynauld JP, Torrance GW, Band PA, Goldsmith CH, Tugwell P, Walker V, Schultz M, Bellamy N; Canadian Knee OA Study Group. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. Osteoarthritis Cartilage 2002 Jul;10(7):506-17. doi: 10.1053/joca.2002.0798. X. Tamer TM. Hyaluronan and synovial joint: function, distribution and healing. Interdiscip Toxicol 2013 Sep;6(3):111-25. doi: 10.2478/intox-2013-0019. XI. Altman RD, Moskowitz R. Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. Hyalgan Study Group. J Rheumatol 1998 Nov;25(11):220312. Erratum in: J Rheumatol 1999 May;26(5):1216. XII. Bogdan-Allemann I, Baumann L. Hyaluronic acid gel (Juvéderm) preparations in the treatment of facial wrinkles and folds. Clin Interv Aging 2008;3(4):629-34. doi: 10.2147/cia.s3118. XIII. Jordan DR. Delayed inflammatory reaction to hyaluronic acid (Restylane). Ophthalmic Plast Reconstr Surg. 2005 Sep;21(5):401-2. doi: 10.1097/01.iop.0000173194.18050.b8. XIV. Ågerup B, Wik O. The MonographnashaTM. 2008. Disponible en: https://docplayer.net/20739410-Nashathe-monograph-1.html. XV. Cornejo P, Alcolea JM, Trelles MA. Perspectivas en el uso de materiales de relleno inyectables para tejidos blandos, desde nuestra experiencia. 1º parte. Cir Plást Iberolatinoam 2011;37(4):393-402. XVI. Smith SR, Jones D, Thomas JA, Murphy DK, Beddingfield FC. Duration of wrinkle correction following repeat treatment with Juvéderm hyaluronic acid fillers. Arch Dermatol Res 2010 Dec;302(10):757-62. doi: 10.1007/ s00403-010-1086-8. XVII. Monheit G, Beer K, Hardas B, Grimes PE, Weichman BM, Lin V, Murphy DK. Safety and effectiveness of the hyaluronic acid dermal filler VYC-17.5L for nasolabial folds. Results of a randomized, controlled study. Dermatol Surg 2018 May;44(5):670-678. doi: 10.1097/ DSS.0000000000001529. XVIII. Galderma. Instrucciones de uso. Disponible en: https:// www.galderma.com/us/sites/default/files/2018-11/ Restylane_IFU.pdf. XIX. Allergan. Instrucciones de uso. Disponible en https:// www.rxabbvie.com/pdf/juvederm-ultra-plus-xc_dfu.pdf. XX. Day DJ, Littler CM, Swift RW, Gottlieb S. The Wrinkle Severity Rating Scale: a validation study. Am J Clin Dermatol 2004;5(1):49-52. doi: 10.2165/00128071200405010-00007. XXI. Savoia A, Accardo C, Vannini F, Di Pasquale B, Baldi A. Outcomes in thread lift for facial rejuvenation: a study performed with happy lift™ tevitalizing. Dermatology Ther (Heidelb) 2014;4(1):103-14. XXII. Sharma AN, Patel BC. Laser Fitzpatrick skin type recommendations (updated 2023 Mar 6). In: StatPearls (Internet). Treasure Island (FL): StatPearls Publishing; 2023 Jan. Disponible en: https://www.ncbi.nlm.nih.gov/ books/NBK557626/. XXIII. Pinsky MA, Thomas JA, Murphy DK, Walker PS; Juvéderm versus Zyplast Nasolabial Fold Study Group. Juvéderm injectable gel: a multicenter, double-blind, randomized study of safety and effectiveness. Aesthet Surg J. 2008 Jan-Feb;28(1):17-23. doi: 10.1016/j.asj.2007.09.005. Publisher An entity responsible for making the resource available Editorial Lugones Date A point or period of time associated with an event in the lifecycle of the resource 12/12/2023 Contributor An entity responsible for making contributions to the resource Allanmar International Company S.R.L Rights Information about rights held in and over the resource Legal records: Lugones® Editorial Seal. Director: Facundo Lugones. Editor: Lic. María Fernanda Cristoforetti. Owner: Editorial Biotecnológica S.R.L. Legal address: Av. Curapaligüe 202, 9° B (1406), City of Buenos Aires, Argentina. Authors of the Lugones article Editorial: Marcelo Robles. Reproduction rights: Lugones® Editorial Seal, Editorial Biotecnológica S.R.L. Total or partial reproduction of the articles is prohibited without the authorization of the author and the publisher. Work registered in the National Directorate of Copyright, Ministry of Justice and Human Rights of the Argentine Republic. Registration of Published Work-Web Page in File No.: RL-2021-41251755-APN-DNDA#MJ. Registration of Periodical Publications in File No.: RL-2023-71140630-APN-DNDA#MJ, City of Buenos Aires, Argentina. Format The file format, physical medium, or dimensions of the resource Website Language A language of the resource Spanish and english Type The nature or genre of the resource Scientific Identifier An unambiguous reference to the resource within a given context <a href="https://www.lugoneseditorial.com.ar/novedades/estudio-de-seguridad-y-eficacia-del-acido-hialuronico-reticulado-en-relleno-de-surcos-nasolabiales/">https://www.lugoneseditorial.com.ar/novedades/estudio-de-seguridad-y-eficacia-del-acido-hialuronico-reticulado-en-relleno-de-surcos-nasolabiales/</a> Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Argentina, 2023 hyaluronic acid crosslinked nasolabial folds skin aging https://ciencia.lugoneseditorial.com.ar/files/original/a722a992e3188d3b542d1f7408ad2425.pdf 706d8ebce706d0dcecbe09b3f98cb768 Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/dermatologia/acido-hialuronico-labios/">https://lugoneseditorial.com.ar/novedades/dermatologia/acido-hialuronico-labios/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Lip volumization with cross-linked hyaluronic acid 18 mg/ml. Efficacy and safety in 102 treated patients Description An account of the resource Introduction: beauty trends have increased the demand for aesthetic procedures, especially the use of hyaluronic acid (HA), to rejuvenate the face and enhance lips. This safe and effective treatment hydrates, fills wrinkles, and restores volume to different areas of the face. HA is obtained from non-animal sources, is non-immunogenic, and possesses antioxidant properties. The perioral region, key to facial aging, is highly sought after for correcting wrinkles, folds, and the loss of definition caused by factors such as age, sun exposure, and lifestyle habits. Cross-linked hyaluronic acid (HRA) is an ideal option for restoring volume to this area. Objectives: to evaluate the safety, efficacy and adverse effects of using HRA 18 mg/ml as a lip filler. Materials and methods: a prospective clinical study included 102 patients (81 women and 21 men), aged 25–65, who required lip volumization and received Cientific Hyaluronic Facial Implant 18® (HRA 18 mg/ml). Treatment efficacy was assessed using the Global Aesthetic Improvement Scale (GAIS). Initial lip volume and perioral wrinkle severity were assessed using the photonumeric scales MERZ (Merz Lip Fullness Scale, MLFS) and Wrinkle Severity Rating Scale (WSRS), respectively. Safety was determined by analyzing local reactions at the injection site and the occurrence of adverse events. The product was administered at a dose of up to 1 ml per half of the lip in an initial application (T0), with follow-ups at 1, 3, and 8 months. If necessary, a single reapplication was performed during these follow-ups. Treatment efficacy was assessed at a final follow-up at 12 months. Results: adverse effects were mild, of immediate onset, common for this type of treatment, which resolved without the need for special treatment. The volumizing effect of HRA 18 mg/ml was effective in 98% of treated patients, with a gradual decrease after 12 months. A significant improvement in lip hydration and firmness was observed. Conclusions: HRA 18 mg/ml is a safe and effective treatment as a dermal filler in lips, with high volume retention and lasting up to 12 months. Patients and professionals experienced high satisfaction, and improvements in skin firmness and elasticity were observed. The results support HRA as a viable and beneficial option in aesthetic medicine. Creator An entity primarily responsible for making the resource Claudio Dachevsky Date A point or period of time associated with an event in the lifecycle of the resource 12/05/2025 Contributor An entity responsible for making contributions to the resource Allanmar Identifier An unambiguous reference to the resource within a given context <a href="https://doi.org/10.47196/0595">https://doi.org/10.47196/0595</a> hyaluronic acid lips perioral area volumization Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/dermatologia/acido-hialuronico-nasolabiales/">https://lugoneseditorial.com.ar/novedades/dermatologia/acido-hialuronico-nasolabiales/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Evaluación de la eficacia y seguridad del ácido hialurónico reticulado 30 mg/ml para relleno de surcos nasolabiales Description An account of the resource Introducción: los surcos nasolabiales (SNL) son una región del rostro con gran movilidad que, durante el envejecimiento, están sometidos a cambios multifactoriales. Cientific Hyaluronic Facial Implant 30® es un relleno de ácido hialurónico reticulado (AHR) de 30 mg/ml desarrollado con el objetivo de optimizar los resultados de esta área facial tan dinámica. Objetivos: evaluar la seguridad y eficacia de Cientific Hyaluronic Facial Implant 30® (CH30), compuesto por AHR 30 mg/ml, para la corrección de SNL de moderados a severos. Materiales y métodos: estudio clínico multicéntrico, prospectivo, de 12 meses de duración, que incluyó 64 pacientes hombres y mujeres de entre 30 y 75 años con SNL de moderados a graves tratados en ambos SNL con CH30 para equilibrar la asimetría hasta lograr una corrección óptima. Las valoraciones de la eficacia por parte de evaluadores incluyeron el análisis de la gravedad de los SNL utilizando la Wrinkle Severity Rating Scale (WSRS) y la mejora con la Global Aesthetic Improvement Scale (GAIS). La seguridad se registró durante todo el estudio en función de los controles en cada cita y la comunicación de los eventos adversos por parte de los pacientes. Resultados: durante los 12 meses de seguimiento no se observaron eventos adversos. En el 100% de los casos, la corrección del defecto, la duración y la satisfacción fueron calificadas por los pacientes y los médicos con puntuaciones de “mejoradas” a “muy mejoradas”, observándose una disminución del efecto muy lento a los 12 meses. Conclusiones: el uso del AHR para el tratamiento de los SNL es una de las opciones más efectivas y seguras en la medicina estética actual. Su capacidad para restaurar el volumen, suavizar las arrugas y mejorar la calidad de la piel lo convierten en una herramienta clave para el rejuvenecimiento facial. La durabilidad de sus resultados, combinada con su baja tasa de complicaciones, hace que el AHR sea ampliamente recomendado para los pacientes que buscan una mejora estética natural y de larga duración, convirtiéndose en una de las intervenciones más populares en la medicina estética moderna. Creator An entity primarily responsible for making the resource Claudio Dachevsky: Médico Cirujano Plástico, Director General, Clínica Lipo Cirugía Plástica, San Pablo, Brasil Source A related resource from which the described resource is derived I. Russell-Goldman E, Murphy GF. The pathobiology of skin aging. New insights into an old dilemma. Am J Pathol 2020 Jul;190(7):1356-1369. doi: 10.1016/j. ajpath.2020.03.007. II. Lupo M. Hyaluronic acid fillers in facial rejuvenation. Seminars in cutaneous medicine and surgery 2006; 25:122-6. doi: 10.1016/j.sder.2006.06.011. III. Duranti F, Salti G, Bovani B, Calandra M, Rosati ML. Injectable hyaluronic acid gel for soft tissue augmentation. A clinical and histological study. Dermatol Surg 1998 Dec;24(12):1317-25. doi: 10.1111/j.1524-4725.1998.tb00007.x. IV. Braccini F, Fanian F, García P, et al Comparative clinical study for the efficacy and safety of two different hyaluronic acid-based fillers with Tri-Hyal versus Vycross technology. A long-term prospective randomized clinical trial. J Cosmet Dermatol 2023 Feb;22(2):473-485. doi: 10.1111/jocd.15200. V. Peña F. Factores relacionados a la durabilidad del ácido hialurónico reticulado. Rev Facultad de Medicina de la Universidad de lberoamérica 2023;2;13-21. doi 10.54376/rcmui.v2i2.148. VI. Wongprasert P, Dreiss CA, Murray G. Evaluating hyaluronic acid dermal fillers. A critique of current characterization methods. Dermatol Ther 2022 Jun;35(6):e15453. doi: 10.1111/dth.15453. VII. Sánchez-Carpintero D, Ruiz-Rodríguez R. Materiales de relleno: tipos, indicaciones y complicaciones. Actas Dermosifiliogr 2010;101(5):381-393. VIII. Bukhari SNA, Roswandi NL, Waqas M, Habib H, Hussain F, et al. Hyaluronic acid, a promising skin rejuvenating biomedicine. A review of recent updates and pre-clinical and clinical investigations on cosmetic and nutricosmetic effects. Int J Biol Macromol. 2018 Dec;120(Pt B):1682-1695. doi: 10.1016/j.ijbiomac.2018.09.188. IX. Martínez-Carpio PA, Vega López PM. Materiales de relleno temporales en medicina estética: revisión de la literatura sobre la incidencia de efectos adversos y complicaciones. Medicina Estética 2019;59(2):14-19. doi: 10.48158/MedicinaEstetica.059.02 X. Cifuentes-Mimoso T, Signes-Soler F. Estudio de efectos adversos tras tratamiento con implantes cutáneos de ácido hialurónico. Universitat Autonoma de Barcelona. Disponible en: https://semcc.com/master/files/Hialuronico%20y%20efectos%20adversos%20-%20Dras.%20Cifuentes%20y%20Signes.pdf. XI. Robles M. Estudio de seguridad y eficacia del ácido hialurónico reticulado en relleno de surcos nasolabiales. doi: 10.47196/0573. XII. Bogdan-Allemann I, Baumann L. Hyaluronic acid gel (Juvéderm) preparations in the treatment of facial wrinkles and folds. Clin Interv Aging 2008;3(4):629-34. Doi: 10.2147/cia.s3118. XIII. Jordan DR. Delayed inflammatory reaction to hyaluronic acid (Restylane). Ophthalmic Plast Reconstr Surg 2005 Sep;21(5):401-2. doi: 10.1097/01.iop.0000173194.18050.b8. XIV. NASHATM. The monograpf. Disponible en: https://es.scribd.com/document/507252742/Monograph-ofNASHA. XV. Cornejo P, Alcolea JM, Trelles MA. Perspectivas en el uso de materiales de relleno inyectables para tejidos blandos, desde nuestra experiencia. 1º parte. Cir Plast Iberolatinoam 2011;37(4):393-402. doi: 10.4321/S037678922011000400013. XVI. Day D, Littler C, Swift R, Gottlieb S. The Wrinkle Severity Scale. American Journal of Clinical Dermatology 2004;5:49-52. doi: 10.2165/00128071-200405010-00007. XVII. Dibernardo G, DiBernardo B. Prediction of treatment outcomes for neck rejuvenation Utilizing a unique classification system of treatment approach using a1440-nm side-firing laser. Aesthetic Surgery Journal 2018;38:S43-S51. doi: 10.1093/asj/sjy066. XVIII. Sundaram H, Shamban A, Schlessinger J, KaufmanJanette J, Joseph JH, Lupin M, Draelos Z, Carey W, Smith S, Eaton L. Efficacy and safety of a new resilient hyaluronic acid filler in the correction of moderateto-severe dynamic perioral rhytides. A 52-week prospective, multicenter, controlled, randomized, evaluator-blinded study. Dermatol Surg. 2022 Jan 1;48(1):87-93. doi: 10.1097/DSS.0000000000003238. XIX. Abduljabbar MH, Basendwh MA. Complications of hyaluronic acid fillers and their managements. Journal of Dermatology & Dermatologic Surgery 2016;20(2). doi: 10.1016/j.jdds.2016.01.001. XX. Instrucciones de uso del producto Cientific Hyaluronic Facial Implant 30. Disponible en: https://es.scribd. com/document/265233528/Cientific-Hyaluronic-FacialImplant-30y18. XXI. Kaufman-Janette J, Taylor SC, Cox SE, Weinkle SH, Smith S, Kinney BM. Efficacy and safety of a new resilient hyaluronic acid dermal filler, in the correction of moderate-to-severe nasolabial folds. A 64-week, prospective, multicenter, controlled, randomized, doubleblind and within-subject study. J Cosmet Dermatol 2019 Oct;18(5):1244-1253. doi: 10.1111/jocd.13100. XXII. Dayan S, Maas CS, Grimes PE, Beer K, Monheit G, Snow S, Murphy DK, Lin V. Safety and effectiveness of VYC17.5L for long-term correction of nasolabial folds. Aesthet Surg J 2020 Jun 15;40(7):767-777. doi: 10.1093/ asj/sjz200. Publisher An entity responsible for making the resource available Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource 31/03/2025 Contributor An entity responsible for making contributions to the resource Allanmar International Company S.R.L Type The nature or genre of the resource DOI: <a href="https://doi.org/10.47196/0590">https://doi.org/10.47196/0590</a> ácido hialurónico ácido hialurónico reticulado Claudio Dachevsky eficacia Hyaluromax Marcelo Robles Rejuvenecimiento facial seguridad surcos nasolabiales https://ciencia.lugoneseditorial.com.ar/files/original/a99411b509f6b3485fb4c2272a46cd81.pdf 4c176201408ce815a005919d9835d6c2 Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/dermatologia/acido-hialuronico-nasolabiales/">https://lugoneseditorial.com.ar/novedades/dermatologia/acido-hialuronico-nasolabiales/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Evaluation of the efficacy and safety of cross-linked hyaluronic acid 30 mg/ml for filling nasolabial folds Description An account of the resource Introduction: the nasolabial folds (NLF) are a highly mobile facial region that undergoes multifactorial changes during aging. Cientific Hyaluronic Facial Implant 30® is a 30 mg/ml cross-linked hyaluronic acid (HRA) filler developed to optimize the results of this highly dynamic facial area. Objectives: to evaluate the safety and efficacy of Cientific Hyaluronic Facial Implant 30® (CH30), composed of 30 mg/ml HRA, for the correction of moderate to severe NLF. Materials and methods: a 12-month, prospective, multicenter clinical study that included 64 male and female patients between 30 and 75 years of age with moderate to severe NLF treated in both NLFs with CH30 to balance the asymmetry until optimal correction was achieved. Efficacy assessments by evaluators included analysis of NLF severity using the Wrinkle Severity Rating Scale (WSRS) and improvement using the Global Aesthetic Improvement Scale (GAIS). Safety was recorded throughout the study based on checks at each appointment and patient reporting of adverse events. Results: no adverse events were observed during the 12-month follow-up. In 100% of cases, defect correction, duration, and satisfaction were rated by patients and physicians as “improved” to “very improved,” with a very slow decrease in effect observed at 12 months. Conclusions: the use of AHR for the treatment of NLF is one of the most effective and safe options in current aesthetic medicine. Its ability to restore volume, smooth wrinkles, and improve skin quality make it a key tool for facial rejuvenation. The durability of the results, combined with its low complication rate, makes HRA widely recommended for patients seeking a natural and longlasting aesthetic improvement, making it one of the most popular interventions in modern aesthetic medicine. Creator An entity primarily responsible for making the resource Claudio Dachevsky: Plastic Surgeon, General Manager, Lipo Plastic Surgery Clinic, São Paulo, Brazil Source A related resource from which the described resource is derived I. Russell-Goldman E, Murphy GF. The pathobiology of skin aging. New insights into an old dilemma. Am J Pathol 2020 Jul;190(7):1356-1369. doi: 10.1016/j. ajpath.2020.03.007. II. Lupo M. Hyaluronic acid fillers in facial rejuvenation. Seminars in cutaneous medicine and surgery 2006; 25:122-6. doi: 10.1016/j.sder.2006.06.011. III. Duranti F, Salti G, Bovani B, Calandra M, Rosati ML. Injectable hyaluronic acid gel for soft tissue augmentation. A clinical and histological study. Dermatol Surg 1998 Dec;24(12):1317-25. doi: 10.1111/ j.1524-4725.1998.tb00007.x. IV. Braccini F, Fanian F, García P, et al Comparative clinical study for the efficacy and safety of two different hyaluronic acid-based fillers with Tri-Hyal versus Vycross technology. A long-term prospective randomized clinical trial. J Cosmet Dermatol 2023. Feb;22(2):473-485. doi: 10.1111/jocd.15200. V. Peña F. Factores relacionados a la durabilidad del ácido hialurónico reticulado. Rev Facultad de Medicina de la Universidad de lberoamérica 2023;2;13-21. doi 10.54376/rcmui.v2i2.148. VI. Wongprasert P, Dreiss CA, Murray G. Evaluating hyaluronic acid dermal fillers. A critique of current characterization methods. Dermatol Ther 2022 Jun;35(6):e15453. doi: 10.1111/dth.15453. VII. Sánchez-Carpintero D, Ruiz-Rodríguez R. Materiales de relleno: tipos, indicaciones y complicaciones. Actas Dermosifiliogr 2010;101(5):381-393. VIII. Bukhari SNA, Roswandi NL, Waqas M, Habib H, Hussain F, et al. Hyaluronic acid, a promising skin rejuvenating biomedicine. A review of recent updates and pre-clinical and clinical investigations on cosmetic and nutricosmetic effects. Int J Biol Macromol. 2018 Dec;120(Pt B):1682-1695. doi: 10.1016/j. ijbiomac.2018.09.188. IX. Martínez-Carpio PA, Vega López PM. Materiales de relleno temporales en medicina estética: revisión de la literatura sobre la incidencia de efectos adversos y complicaciones. Medicina Estética 2019;59(2):14-19. doi: 10.48158/MedicinaEstetica.059.02 X. Cifuentes-Mimoso T, Signes-Soler F. Estudio de efectos adversos tras tratamiento con implantes cutáneos de ácido hialurónico. Universitat Autonoma de Barcelona. Disponible en: https://semcc.com/master/files/Hialuronico%20y%20efectos%20adversos%20-%20Dras.%20Cifuentes%20y%20Signes.pdf. XI. Robles M. Estudio de seguridad y eficacia del ácido hialurónico reticulado en relleno de surcos nasolabiales. doi: 10.47196/0573. XII. Bogdan-Allemann I, Baumann L. Hyaluronic acid gel (Juvéderm) preparations in the treatment of facial wrinkles and folds. Clin Interv Aging 2008;3(4):629-34. Doi: 10.2147/cia.s3118. XIII. Jordan DR. Delayed inflammatory reaction to hyaluronic acid (Restylane). Ophthalmic Plast Reconstr Surg 2005 Sep;21(5):401-2. doi: 10.1097/01.iop.0000173194.18050.b8. XIV. NASHATM. The monograpf. Disponible en: https://es.scribd.com/document/507252742/Monograph-ofNASHA. XV. Cornejo P, Alcolea JM, Trelles MA. Perspectivas en el uso de materiales de relleno inyectables para tejidos blandos, desde nuestra experiencia. 1º parte. Cir Plast Iberolatinoam 2011;37(4):393-402. doi: 10.4321/S037678922011000400013. XVI. Day D, Littler C, Swift R, Gottlieb S. The Wrinkle Severity Scale. American Journal of Clinical Dermatology 2004;5:49-52. doi: 10.2165/00128071-200405010-00007. XVII. Dibernardo G, DiBernardo B. Prediction of treatment outcomes for neck rejuvenation Utilizing a unique classification system of treatment approach using a 1440-nm side-firing laser. Aesthetic Surgery Journal 2018;38:S43-S51. doi:10.1093/asj/sjy066. Ther 2022 XVIII. Sundaram H, Shamban A, Schlessinger J, Kaufman. Janette J, Joseph, JH, Lupin M, Draelos Z, Carey W, Smith S, Eaton L. Efficacy and safety of a new resilient hyaluronic acid filler in the correction of moderateto-severe dynamic perioral rhytides. A 52-week prospective, multicenter, controlled, randomized, evaluator-blinded study. Dermatol Surg. 2022 Jan 1;48(1):87-93. doi: 10.1097/DSS.0000000000003238. XIX. Abduljabbar MH, Basendwh MA. Complications of hyaluronic acid fillers and their managements. Journal of Dermatology & Dermatologic Surgery 2016;20(2). doi: 10.1016/j.jdds.2016.01.001. XX. Instrucciones de uso del producto Cientific Hyaluronic Facial Implant 30. Disponible en: https://es.scribd.com/document/265233528/Cientific-Hyaluronic-FacialImplant-30y18. XXI. Kaufman-Janette J, Taylor SC, Cox SE, Weinkle SH, Smith S, Kinney BM. Efficacy and safety of a new resilient hyaluronic acid dermal filler, in the correction of moderate-to-severe nasolabial folds. A 64-week, prospective, multicenter, controlled, randomized, doubleblind and within-subject study. J Cosmet Dermatol 2019 Oct;18(5):1244-1253. doi: 10.1111/jocd.13100. XXII. Dayan S, Maas CS, Grimes PE, Beer K, Monheit G, Snow S, Murphy DK, Lin V. Safety and effectiveness of VYC17.5L for long-term correction of nasolabial folds. Aesthet Surg J 2020 Jun 15;40(7):767-777. doi: 10.1093/asj/sjz200. Publisher An entity responsible for making the resource available Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource 31/03/2025 Contributor An entity responsible for making contributions to the resource Allanmar International Company S.R.L Identifier An unambiguous reference to the resource within a given context DOI: https://doi.org/10.47196/0590 Claudio Dachevsky Cross-linked hyaluronic acid Effectiveness Facial rejuvenation Hyaluromax hyaluronic acid Marcelo Robles nasolabial folds safety Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/dermatologia/terapia-oral-psoriasis-deucravacitinib/">https://lugoneseditorial.com.ar/novedades/dermatologia/terapia-oral-psoriasis-deucravacitinib/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Terapia oral innovadora para la psoriasis Description An account of the resource Con una alta eficacia y un perfil de seguridad favorable, deucravacitinib resulta una terapia oral innovadora para la psoriasis en placas de moderada a severa. Su vía oral es una gran ventaja y promete mejorar significativamente el manejo de la enfermedad. Creator An entity primarily responsible for making the resource Claudio Greco, Médico Dermatólogo, Miembro del Grupo de Psoriasis y Vitiligo de la Sociedad Argentina de Dermatología, Coordinador del Grupo de Hidradenitis Supurativa Source A related resource from which the described resource is derived I. Warren RB, et al. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in plaque psoriasis. Psoriasis Area and Severity Index (PASI) outcomes over 4 years in patients receiving continuous deucravacitinib in the phase 3 POETYK PSO-1, PSO-2, and LTE trials. Presented at the 33rd European Academy of Dermatology & Venereology (EADV) Congress; 25-28 September 2024; Amsterdam, Netherlands. II. Warren RB, et al. Deucravacitinib in plaque psoriasis. 4-year efficacy results by prior biologic treatment in the phase 3 POETYK PSO-1, PSO-2, and LTE trials. Presented at the 33rd European Academy of Dermatology & Venereology (EADV) Congress; 25-28 September 2024; Amsterdam, Netherlands. III. Thaçi D, et al. Deucravacitinib efficacy in patients with moderate to severe psoriasis with scalp and fingernail disease. Response over 4 years of treatment in the phase 3 POETYK PSO-1, PSO-2, and LTE trials. Presented at the 33rdEuropean Academy of Dermatology & Venereology (EADV) Congress; 25-28 September 2024; Amsterdam, Netherlands. IV. Thaçi D, et al. Deucravacitinib efficacy in Psoriasis Area and Severity Index (PASI) target outcomes through 4 years in the phase 3 POETYK trials in moderate to severe plaque psoriasis Presented at the 33rd European Academy of Dermatology & Venereology (EADV) Congress; 25-28 September 2024; Amsterdam, Netherlands. V. Gooderham MJ, Hong CH, Litvinov IV. Selective TYK2 inhibition in the treatment of moderate to severe chronic plaque psoriasis. Skin Therapy Letter 2022;27(6). VI. Armstrong AW, Warren RB, Zhong Y, et al. Short-, mid-, and long-term efficacy of deucravacitinib versus biologics and nonbiologics for plaque psoriasis. A network meta-analysis. Dermatology and Therapy. 2023 Nov;13(11):2839-2857. Publisher An entity responsible for making the resource available Lic. María Fernanda Cristoforetti, Editora de Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource 13/12/2024 Contributor An entity responsible for making contributions to the resource Bristol Myers Language A language of the resource Español Bristol Claudio Greco Deucravacitinib eficacia Perfil de seguridad Psoriasis Psoriasis en placa Terapia oral Infección por dengue en diabetes